GI Innovation said on the 3rd that it will present on an immuno-oncology drug at the American Society of Clinical Oncology (ASCO). It is a venue for sharing the latest clinical information on oncology and is regarded as one of the world's three major cancer conferences.
GI Innovation will give an oral presentation on phase 1 data for the immuno-oncology drug "GI-101A." Based on real-world patient data, the clinical value of the new drug is expected to be assessed.
The American Society of Clinical Oncology will be held in Chicago from May 29 to June 3. Jang Myeong-ho, CEO of GI Innovation, said, "The clinical potential and academic value of the immuno-oncology drug have been recognized."
※ This article has been translated by AI. Share your feedback here.